Travere Therapeutics (TVTX) Inventory (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Inventory came in at $6.4 million in Q1 2026, up 61.65% YoY from $3.9 million in Q1 2025, and up 8.19% on a QoQ basis from $5.9 million in Q4 2025.
Travere Therapeutics (TVTX) Inventory (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Inventory data on file, last reported at $6.4 million in Q1 2026.
- Quarterly Inventory rose 61.65% year-over-year to $6.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.4 million (up 61.65% YoY) and the FY2025 annual result came in at $5.9 million, down 5.24% from the prior year.
- Inventory climbed to $6.4 million in Q1 2026, from $5.9 million in the prior quarter.
- In the past five years, Inventory ranged from a high of $20.8 million in Q3 2023 to a low of $3.9 million in Q1 2025.
- A 5-year average of $7.7 million and a median of $6.4 million in 2024 frame the typical range for Inventory.
- Annual changes were most pronounced in 2023 — Inventory jumped 184.68% — and 2024, when it slumped 69.4%.
- Tracing TVTX's Inventory over 5 years: stood at $4.5 million in 2022, then jumped by 108.05% to $9.4 million in 2023, then tumbled by 34.11% to $6.2 million in 2024, then decreased by 5.24% to $5.9 million in 2025, then grew by 8.19% to $6.4 million in 2026.
- The last three Inventory figures came in at $6.4 million (Q1 2026), $5.9 million (Q4 2025), and $5.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inventory (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.77 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.08 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 371.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 732.60 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 358,916.96 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 97.11 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 142.38 Mn |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 7.84 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.84 Mn |
| Mar 31, 2026 | 6.36 Mn |
| Dec 31, 2025 | 5.88 Mn |
| Sep 30, 2025 | 5.55 Mn |
| Jun 30, 2025 | 4.09 Mn |
| Mar 31, 2025 | 3.93 Mn |
| Dec 31, 2024 | 6.20 Mn |
| Sep 30, 2024 | 6.36 Mn |
| Jun 30, 2024 | 5.98 Mn |
| Mar 31, 2024 | 4.53 Mn |
| Dec 31, 2023 | 9.41 Mn |
| Sep 30, 2023 | 20.77 Mn |
| Jun 30, 2023 | 18.77 Mn |
| Mar 31, 2023 | 6.71 Mn |
| Dec 31, 2022 | 4.52 Mn |
| Sep 30, 2022 | 7.30 Mn |
| Jun 30, 2022 | 7.63 Mn |
| Mar 31, 2022 | 6.52 Mn |
| Dec 31, 2021 | 7.31 Mn |
| Sep 30, 2021 | 6.62 Mn |